

ACC HIGHLIGHTS

2025



**TUESDAY,
APRIL 15**

7:00 – 8:30 pm EDT

Program Overview:

This program will cover the key clinical trial findings and their implications from ACC 2025. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

SOUL– Cardiovascular benefits of an oral GLP-1 receptor agonist

RIVAWAR - Rivaroxaban vs. warfarin for acute LV thrombus post-MI

STRIDE– Clinical effects of weekly semaglutide in patients with peripheral arterial disease

TAVR Updates – The role of TAVR in aortic insufficiency and in low-risk aortic stenosis

Learning Objectives:

- Review trials and data presented at ACC 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



Register Now!

Visit: www.ccrnmd.com

For inquiries regarding this program, please contact info@ccrnmd.com



Developed by:
 **CCRN**
Collaborative CME and Research Network

SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,
Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director,
NSC Cardiology Clinical Assistant
Professor,
Medical College of Georgia at
Augusta University & Mercer University
Atlanta, GA

This program was developed by CCRN and received an unrestricted educational grant from Novo Nordisk